237 related articles for article (PubMed ID: 10102350)
1. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
4. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
6. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
7. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
9. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
[TBL] [Abstract][Full Text] [Related]
11. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Lev-Chelouche D; Abu-Abeid S; Nakache R; Issakov J; Kollander Y; Merimsky O; Meller I; Klausner JM; Gutman M
Surgery; 1999 Nov; 126(5):963-7. PubMed ID: 10568198
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
Lans TE; Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
Ann Surg Oncol; 2005 May; 12(5):406-11. PubMed ID: 15915375
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
14. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
[TBL] [Abstract][Full Text] [Related]
17. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
Jakob J; von Rege I; Weiss C; Hohenberger P
Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
[TBL] [Abstract][Full Text] [Related]
19. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
20. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
Jakob J; Hohenberger P
Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]